CAS: 910463-68-2
MF: C187H291N45O59
MW: 4113.57754
EINECS: 203-405-2
Solubility DMSO: 3mg/mL (0.73 mM)

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. It mimics the GLP-1 hormone, released in the gut in response to eating.
One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood sugar (glucose). For that reason, health care providers have used semaglutide for more than 15 years to treat Type 2 diabetes.
But GLP-1 in higher amounts also interacts with the parts of the brain that suppress your appetite and signal you to feel full. When used in conjunction with diet and exercise, it can cause significant weight loss - and a reduced risk of cancer, diabetes and heart disease - in people who are obese or overweight.
Currently, semaglutide is only approved for weight loss. The typical dose for weight loss is 2.4 milligrams, administered weekly as subcutaneous (under the skin) self-injections.
This medication is for injection under the skin of your upper leg (thigh), stomach area, or upper arm. It is given once every week (every 7 days). You will be taught how to prepare and give this medication. Use exactly as directed. Take your medication at regular intervals. Do not take it more often than directed.
The side effects of semaglutide are typically mild - especially when compared to the complications associated with overweight and obesity.
Népszerű tags:












